GleamWall
中文EN

AKTX Akari Therapeutics Plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1541157 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-86.4%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-146.3%
ROA-71.8%
ROIC (approx.)-140.0%
Asset turnover—

Leverage & solvency

Liabilities / assets52.2%
Debt / equity0.00x
Current ratio0.48x
Interest coverage-282.65x

Cash quality & payout

Operating cash flow / net income0.44x
Accruals ratio-40.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.11M$2.08M$1.46M$1.09M$249,000$667,000$813,000$1.25M
SG&A expense$2.57M$2.52M$2.17M$2.14M$1.98M$2.45M$2.71M$3.05M
Operating income-$4.68M-$4.60M-$15.76M-$3.23M-$7.40M-$3.12M-$3.52M-$5.28M
Interest expense$85,000$80,000$61,000-$126,000$121,000$50,000$55,000$124,000
Pretax income-$4.84M-$4.81M-$15.31M-$5.21M-$7.49M-$1.90M-$3.71M-$3.77M
Income tax$0$0-$859,000$85,000-$1.09M$0$0—
Net income-$4.84M-$4.81M-$14.46M-$5.30M-$6.40M-$1.90M-$3.71M-$3.77M
EBITDA———————-$5.28M
EPS (basic)0.000.000.00—0.000.000.00—
EPS (diluted)0.000.000.00—0.000.000.00—
Weighted avg. shares (diluted)265.89B143.32B118.76B—65.33B62.94B54.59B—
Balance sheet
Cash & equivalents$5.74M$7.69M$2.77M$5.20M$2.54M$2.77M$2.64M$2.66M
Current assets$6.28M$8.32M$3.59M$5.46M$2.95M$3.30M$3.35M$2.95M
Goodwill———$8.43M$8.43M$8.43M$8.43M$8.43M
Total assets$36.58M$38.62M$33.89M$47.89M$45.38M$50.91M$50.96M$50.56M
Current liabilities$12.98M$13.94M$13.41M$12.35M$15.57M$17.14M$20.91M$19.91M
Total liabilities$19.08M$20.03M$19.51M$19.56M$22.69M$25.31M$29.21M$28.33M
Shareholders' equity$17.50M$18.59M$14.38M$28.33M$22.69M$25.61M$21.75M$22.23M
Shares outstanding182.81B140.03B91.57B90.54B65.23B65.23B57.75B53.19B
Cash flow statement
Operating cash flow-$4.22M-$3.11M-$2.49M-$3.04M-$2.12M-$3.26M-$2.15M-$2.12M
Financing cash flow$2.27M$8.04M$53,000$5.76M$1.90M$3.38M$2.13M$2.15M
Depreciation & amortization———————$1,000
Stock-based compensation$537,000$711,000$305,000$471,000$685,000$719,000$1.01M$1.26M

Free plan shows the latest 8 periods; Pro shows all 41 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.